D. Medical Announces the Filling of a Shelf Prospectus in Israel
11 Setembro 2011 - 2:22PM
Marketwired
D. Medical Industries Ltd. (NASDAQ: DMED)(TASE: DMED) ("D. Medical"
or the "Company"), a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery,
announced that the Company published today a shelf prospectus (the
"Shelf Prospectus") in Israel.
The Shelf Prospectus is valid for a period of two years and may
be used by the Company to raise capital or debt in the future
through the issuance of shares (including pursuant to the SEDA
entered into with Yorkville), bonds, convertible bonds and/or
warrants to purchase shares or bonds, at the discretion of the
Company, subject to a supplemental shelf offering report in which
the Company would describe the specific details of the offering,
including the terms of the securities offered.
The Company has not yet made any decision as to the offering of
any securities, nor as to its scope, terms or timing, nor is there
any certainty that such an offering will be made. A public
offering, if made, will be made in Israel.
Securities, if offered, will not be registered under the U.S.
Securities Act of 1933, as amended, and will not be offered or sold
in the United States absent registration or applicable exemption
from the registration requirements. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
any securities.
About D. Medical
D. Medical is a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery. D.
Medical has developed durable and semi-disposable insulin pumps,
which continuously infuse insulin into a patient's body, using its
proprietary spring-based delivery technology. D. Medical believes
that its spring-based delivery mechanism is cost-effective compared
to the motor and gear train mechanisms that drive competitive
insulin pumps and also allows it to incorporate certain
advantageous functions and design features in its insulin pumps. D.
Medical has also developed an infusion set for insulin pumps and is
focusing its research and development efforts on the development of
next generation insulin pumps and a device that will combine a
continuous glucose monitoring system and an insulin pump on the
same patch. For more information, please visit
http://www.dmedicalindustries.com (corporate) and
http://www.springnow.com (healthcare professionals, patients and
care givers).
Forward-Looking Statements
This press release contains forward-looking statements (as
defined by the Israeli Securities Law, 1968, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended) that involve risks and
uncertainties. No assurances can be given that any of the events
anticipated by the forward-looking statements will transpire or
occur, or of any of them will transpire or occur, what impact it
will have on D. Medical's results of operations or financial
condition. D. Medical does not undertake to update any
forward-looking statements.
Contacts: Company Contact: D. Medical Industries LTD Amir
Loberman Chief Financial Officer T: +972-73-2507135
info@springnow.com North American Investor Contact: D. Medical
Industries LTD Stephen Kilmer T: 212.618.6347 or M: 905-906-6908
stephen@dmedicalindustries.com Israeli Investor Relations Iris
Lubitch T: +972-775538007 Iris@EffectiveIR.co.il
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024